ARS Pharmaceuticals To Present Clinical Efficacy Data For neffy At 2024 AAAAI Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced it will present clinical efficacy data for neffy, an epinephrine nasal spray, at the 2024 AAAAI meeting. The data includes 100% response rate in pediatric anaphylaxis cases from oral food challenges and significant reductions in urticaria symptoms. The company is on track to report topline results from a repeat dose study in Q1 2024, with an NDA re-submission expected in mid-H1 2024. The presentations aim to support post-marketing promotion of neffy, pending approval.
February 05, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals, Inc. is set to present promising clinical data for neffy, indicating a strong potential for regulatory approval and market success.
The positive clinical efficacy data for neffy, including a 100% response rate in pediatric anaphylaxis cases and significant reductions in urticaria symptoms, are likely to be viewed positively by investors and could lead to increased investor confidence in ARS Pharmaceuticals' potential for regulatory approval and market success. The announcement of the NDA re-submission timeline further supports the potential for neffy's approval and commercialization, which could significantly impact SPRY's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100